Clinical investigation of use of Episil® oral solution in oral mucositis during radiotherapy for head and neck cancer

Ito, Katsuya; Tokura, Shiori; Takazawa, Itsuki; Yoshida, Naomi; Nakanishi, Tohko; Akiyama, Kikue; Onuma, Yuki; Adachi, Tomiro; Harada, Hiroyuki; Nojima, Hitomi; Miura, Masahiko; Yoshimura, Ryoichi; Kabasawa, Yuji

doi:10.1016/j.heliyon.2023.e15869

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In relation to the clinical aspects of LLCNs, Episil (Solasia Pharma, Tokyo, Japan), a bioadhesive oral liquid formulation comprising phosphatidylcholine and GDO-based LLCNs to treat oral mucositis-associated pain in patients, demonstrated the potential development for safe and long-term application. 31 Recently, another LLCN-based product, Brixadi (buprenorphine) extended release, is approved by the U.S. FDA for the treatment of moderate to severe opioid use disorder via subcutaneous injection. 32 Brixadi will be available in the U.S. healthcare setting in September 2023.…”

Section: Introductionmentioning

confidence: 99%

Coencapsulation of Gemcitabine and Thymoquinone in Citrem–Phosphatidylcholine Hexosome Nanocarriers Improves In Vitro Cellular Uptake in Breast Cancer Cells

Loo,

Zahid,

Madheswaran

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Lyotropic liquid crystalline nanoassemblies (LLCNs) are internally self-assembled (ISA)-somes formed by amphiphilic molecules in a mixture comprising a lipid, stabilizer, and/or surfactant and aqueous media/dispersant. LLCNs are unique nanoassemblies with versatile applications in a wide range of biomedical functions. However, they comprise a nanosystem that is yet to be fully explored for targeted systemic treatment of breast cancer. In this study, LLCNs proposed for gemcitabine and thymoquinone (Gem-TQ) co-delivery were prepared from soy phosphatidylcholine (SPC), phytantriol (PHYT), or glycerol monostearate (MYVR) in optimized ratios containing a component of citric and fatty acid ester-based emulsifier (Grinsted citrem) or a triblock copolymer, Pluronic F127 (F127). Hydrodynamic particle sizes determined were below 400 nm (ranged between 96 and 365 nm), and the series of nanoformulations displayed negative surface charge. Nonlamellar phases identified by small-angle X-ray scattering (SAXS) profiles comprise the hexagonal, cubic, and micellar phases. In addition, high entrapment efficiency that accounted for 98.3 ± 0.1% of Gem and 99.5 ± 0.1% of TQ encapsulated was demonstrated by the coloaded nanocarrier system, SPC/citrem/Gem-TQ hexosomes. Low cytotoxicity of SPC-citrem hexosomes was demonstrated in MCF10A cells consistent with hemo- and biocompatibility observed in zebrafish (Danio rerio) embryos for up to 96 h postfertilization (hpf). SPC/citrem/Gem-TQ hexosomes demonstrated IC50 of 24.7 ± 4.2 μM in MCF7 breast cancer cells following a 24 h treatment period with the moderately synergistic interaction between Gem and TQ retained (CI = 0.84). Taken together, biocompatible SPC/citrem/Gem-TQ hexosomes can be further developed as a multifunctional therapeutic nanodelivery approach, plausible for targeting breast cancer cells by incorporation of targeting ligands.

show abstract

Section: Introductionmentioning

confidence: 99%